[[ type === 'moc' ? 'MARKET ON CLOSE' : 'FREE WEBINAR' ]]
[[ timeLabel ]] WATCH LIVE:
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Rhythm Pharmaceuticals Inc (RYTM)

Rhythm Pharmaceuticals Inc (RYTM)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]] ([[ financialData.relativeStrengthDirection14d ]]) ([[ financialData.highPercent1y ]]) ([[ financialData.lowPercent1y ]])
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 7,924,470
  • Shares Outstanding, K 68,533
  • Annual Sales, $ 189,760 K
  • Annual Income, $ -196,540 K
  • EBIT $ -197 M
  • EBITDA $ -196 M
  • 60-Month Beta 1.92
  • Price/Sales 40.49
  • Price/Cash Flow N/A
  • Price/Book 74.60

Options Overview Details

View History
  • Implied Volatility 47.54% (-5.19%)
  • Historical Volatility 42.05%
  • IV Percentile 15%
  • IV Rank 12.69%
  • IV High 106.20% on 12/02/25
  • IV Low 39.01% on 08/11/25
  • Expected Move (DTE 12) 3.68 (3.18%)
  • Put/Call Vol Ratio 1.70
  • Today's Volume 27
  • Volume Avg (30-Day) 122
  • Put/Call OI Ratio 0.35
  • Today's Open Interest 3,610
  • Open Int (30-Day) 3,072
  • Expected Range 111.95 to 119.31

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 18 analysts offering recommendations.
Earnings Estimates - Current Qtr 09/30/26
See More
  • Average Estimate $-0.69
  • Number of Estimates 6
  • High Estimate $-0.57
  • Low Estimate $-0.80
  • Prior Year $-0.82
  • Growth Rate Est. (year over year) +15.85%

Price Performance

See More
Period Period Low Period High Performance
1-Month
97.57 +18.52%
on 08/04/26
116.18 -0.47%
on 08/07/26
+1.17 (+1.02%)
since 07/07/26
3-Month
82.89 +39.50%
on 06/02/26
116.18 -0.47%
on 08/07/26
+19.40 (+20.16%)
since 05/07/26
52-Week
74.50 +55.21%
on 03/30/26
122.20 -5.38%
on 12/11/25
+23.15 (+25.03%)
since 08/07/25

Most Recent Stories

More News
Rhythm Pharmaceuticals Announces Participation in Upcoming Investor Conferences

BOSTON, Aug. 04, 2026 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a global commercial-stage biopharmaceutical company focused on transforming the lives of patients living with rare...

RYTM : 115.63 (+3.15%)
Rhythm Pharmaceuticals Reports Second Quarter 2026 Financial Results and Business Update

-- U.S. launch of IMCIVREE ® (setmelanotide) for acquired hypothalamic obesity (HO) starts strong with more than 400 patient start forms since FDA approval as of June 30, 2026 -- -- Second...

RYTM : 115.63 (+3.15%)
Rhythm Pharmaceuticals Announces Preliminary Data from Phase 2 Trial that Showed RM-718 Demonstrated Positive Efficacy Signal in Acquired Hypothalamic Obesity

-- -11.6% mean reduction in BMI from baseline at Week 16 (n=7) -- -- BMI reductions consistent with setmelanotide and bivamelagon -- -- Management to host conference call to discuss second quarter...

RYTM : 115.63 (+3.15%)
Kuehn Law Encourages Investors of Rhythm Pharmaceuticals, Inc. to Contact Law Firm

NEW YORK , July 21, 2026 /PRNewswire/ -- Kuehn Law, PLLC, a shareholder litigation law firm, is investigating whether certain officers and directors of Rhythm Pharmaceuticals, Inc. (NASDAQ:...

RYTM : 115.63 (+3.15%)
Rhythm Pharmaceuticals to Report Second Quarter 2026 Financial Results on Tuesday, August 4, 2026

BOSTON, July 21, 2026 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a global commercial-stage biopharmaceutical company focused on transforming the lives of patients living with rare...

RYTM : 115.63 (+3.15%)
Rhythm Pharmaceuticals Announces The New England Journal of Medicine Publication of Phase 3 TRANSCEND Trial Results in Acquired Hypothalamic Obesity

BOSTON, July 08, 2026 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a global commercial-stage biopharmaceutical company focused on transforming the lives of patients living with rare...

RYTM : 115.63 (+3.15%)
Intel Stock and 3 Other Winners I Found Using Barchart’s High-Octane Stock Screener

One feature within the Barchart Stock Screener tool that resonated with me is a pre-built filter known as the J-Pattern or J-Curve.

INTC : 101.65 (+1.84%)
RYTM : 115.63 (+3.15%)
$SPX : 7,757.64 (+0.62%)
GEV : 990.32 (-1.00%)
MRNA : 59.17 (+9.86%)
Rhythm Pharmaceuticals Announces Multiple New Data Presentations from MC4R Agonists in Acquired Hypothalamic Obesity (HO), Bardet-Biedl Syndrome (BBS) and Prader-Willi Syndrome (PWS) at ENDO 2026

 -- Setmelanotide therapy achieved robust, sustained and clinically significant weight loss in patients with acquired HO at 2.5 years -- - - Bivamelagon therapy achieved progressive reductions...

RYTM : 115.63 (+3.15%)
 Rhythm Pharmaceuticals Presents Positive Interim Six-month Data from Phase 2 Trial of Setmelanotide in Patients with Prader-Willi Syndrome (PWS) at ENDO 2026

 -- Patients with PWS treated with setmelanotide therapy (N=17) achieved clinically meaningful BMI or BMI z-score reductions, reductions in fat mass with preservation of lean mass, and improvements in...

RYTM : 115.63 (+3.15%)
Rhythm Pharmaceuticals to Announce Interim Six-Month Phase 2 Results Evaluating Setmelanotide in Patients with Prader-Willi Syndrome

BOSTON, June 12, 2026 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a global commercial-stage biopharmaceutical company focused on transforming the lives of patients living with rare...

RYTM : 115.63 (+3.15%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 88% Buy with a Strongest short term outlook on maintaining the current direction.

See More Share

Business Summary

Rhythm Pharmaceuticals, Inc. is a biopharmaceutical company. It focused on the development and commercialization of peptide therapeutics for the treatment of rare genetic deficiencies which result in life-threatening metabolic disorders. The Company's product candidate principally consists of setmelanotide,...

See More

Key Turning Points

3rd Resistance Point 121.80
2nd Resistance Point 118.99
1st Resistance Point 117.31
Last Price 115.63
1st Support Level 112.82
2nd Support Level 110.01
3rd Support Level 108.33

See More

52-Week High 122.20
Last Price 115.63
Fibonacci 61.8% 103.98
Fibonacci 50% 98.35
Fibonacci 38.2% 92.72
52-Week Low 74.50

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.